162 related articles for article (PubMed ID: 25275295)
41. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
42. GLUT-1 expression and response to chemoradiotherapy in rectal cancer.
Brophy S; Sheehan KM; McNamara DA; Deasy J; Bouchier-Hayes DJ; Kay EW
Int J Cancer; 2009 Dec; 125(12):2778-82. PubMed ID: 19569052
[TBL] [Abstract][Full Text] [Related]
43. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
[TBL] [Abstract][Full Text] [Related]
44. [A case of long-term survival after resection of advanced undifferentiated rectal cancer treated by short-term preoperative chemoradiotherapy and postoperative adjuvant chemotherapy].
Naito Y; Hashiguchi Y; Ueno H; Kajiwara Y; Shimazaki H; Mochizuki H; Hase K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):117-20. PubMed ID: 21368471
[TBL] [Abstract][Full Text] [Related]
45. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
46. Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Okugawa Y; Fujikawa H; Matsushita K; Uchida K; Inoue Y; Kusunoki M
Surg Today; 2012 May; 42(5):460-9. PubMed ID: 22072148
[TBL] [Abstract][Full Text] [Related]
47. Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost.
Appelt AL; Vogelius IR; Pløen J; Rafaelsen SR; Lindebjerg J; Havelund BM; Bentzen SM; Jakobsen A
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):110-8. PubMed ID: 25015203
[TBL] [Abstract][Full Text] [Related]
48. Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population.
El Otmani I; El Agy F; El Baradai S; Bouguenouch L; Lahmidani N; El Abkari M; Benajah DA; Toughrai I; El Bouhaddouti H; Mouaqit O; Ibn Majdoub Hassani K; Mazaz K; Benjelloun EB; Ousadden A; El Rhazi K; Bouhafa T; Benbrahim Z; Ouldim K; Ibrahimi SA; Ait Taleb K; Chbani L
Dis Markers; 2020; 2020():8459303. PubMed ID: 31998419
[TBL] [Abstract][Full Text] [Related]
49. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
50. C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery.
Toiyama Y; Inoue Y; Saigusa S; Kawamura M; Kawamoto A; Okugawa Y; Hiro J; Tanaka K; Mohri Y; Kusunoki M
Anticancer Res; 2013 Nov; 33(11):5065-74. PubMed ID: 24222151
[TBL] [Abstract][Full Text] [Related]
51. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
Vestermark LW; Jensen HA; Pfeiffer P
Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062
[TBL] [Abstract][Full Text] [Related]
52. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
[TBL] [Abstract][Full Text] [Related]
53. Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer.
Atasoy BM; Abacioglu U; Dane F; Ozgen Z; Yumuk PF; Ozden S; Akgun Z; Mayadagli A; Basaran G; Turhal S; Sengoz M
J BUON; 2007; 12(2):203-8. PubMed ID: 17600873
[TBL] [Abstract][Full Text] [Related]
54. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.
Ock CY; Son B; Keam B; Lee SY; Moon J; Kwak H; Kim S; Kim TM; Jeon YK; Kwon SK; Hah JH; Lee SH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):873-83. PubMed ID: 26677030
[TBL] [Abstract][Full Text] [Related]
55. p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma.
Luna-Perez P; Arriola EL; Cuadra Y; Alvarado I; Quintero A
Ann Surg Oncol; 1998; 5(3):203-8. PubMed ID: 9607618
[TBL] [Abstract][Full Text] [Related]
56. Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer.
Ng SY; Colborn KL; Cambridge L; Cercek A; Reidy-Lagunes DL; Segal N; Stadler Z; Saltz LB; Paty PB; Guillem J; Weiser MR; Nash G; Garcia-Aguilar J; Goodman KA
Clin Colorectal Cancer; 2019 Sep; 18(3):167-174. PubMed ID: 31104990
[TBL] [Abstract][Full Text] [Related]
57. [Detection and clinical significance of apoptosis related protein in local advanced rectal cancer patients with preoperative neoadjuvant therapy].
Liu Y; Zhang G; Qian J; Zhu YP; Ju HX; Feng HY; Zhu HN; Li DC
Zhonghua Wai Ke Za Zhi; 2012 Oct; 50(10):914-7. PubMed ID: 23302463
[TBL] [Abstract][Full Text] [Related]
58. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
[TBL] [Abstract][Full Text] [Related]
59. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?
Habr-Gama A; Sabbaga J; Gama-Rodrigues J; São Julião GP; Proscurshim I; Bailão Aguilar P; Nadalin W; Perez RO
Dis Colon Rectum; 2013 Oct; 56(10):1109-17. PubMed ID: 24022527
[TBL] [Abstract][Full Text] [Related]
60. Absence of cyclooxygenase-2 protein expression is a predictor of tumor regression in rectal cancer treated with preoperative short-term chemoradiotherapy.
Kobayashi H; Hashiguchi Y; Ueno H; Shinto E; Kajiwara Y; Mochizuki H
Dis Colon Rectum; 2007 Sep; 50(9):1354-62. PubMed ID: 17308999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
